NATS ministers sparked fury for appearing to suggest that sending male-bodied trans convicts to women’s prisons is like mums ...

On track to define optimal dosing interval and advance manufacturing scale up of REYOBIQ for pivotal trial readiness in late ...

India’s EVs are on the upswing but is the charging network ready? Read on to understand the technology and planning that ...

The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug ...

In today's healthcare environment, securing regulatory approval is only the beginning. The real challenge lies in ensuring ...

ALX Oncology (NASDAQ:ALXO) outlined progress across its two clinical-stage programs—CD47 blocker evorpacept and EGFR-targeted ...

RAPT Therapeutics, Inc. is being acquired by GSK plc for $2.2B as ozureprubart targets IgE disorders with 8–12 week dosing.

The EMA has started its review of Daiichi Sankyo and AstraZeneca's Enhertu as a first-line therapy for HER2-positive breast ...

Dr Ray O’Connor takes a look at recent clinical articles on the importance of promoting vaccines for Measles, HIV, Gonorrhoea ...

Oncoscope launches the first Real-time, AI-supported Living Systematic Literature Review designed for enterprise-wide ...

One extra zero added to a bank check can mean the difference between losing $100 and losing $1,000. In many cases, such ...

Building materials retailer Cashbuild has failed in its attempt to overturn a ruling that found the dismissal of one of its employees substantively unfair. The Labour Court in Johannesburg dismissed ...